In a new study published in online journal Oncogene researchers concluded that combining two microRNAs in an animal model of non-small-cell lung cancer suppressed tumor growth. This research may offer a less toxic and more direct method for targeting relevant pathways used by tumor cells. This research supplements clinical trials and pre-clinical models evaluating single microRNAs as key therapeutic agents for cancer. Researchers said “Targeted cancer therapies are often used in combination to help offset primary or secondary resistance.” ..We know that microRNAs target many oncogenes, We, therefore, hypothesized that a combination of two miRNAs could similarly offset resistance.”
“Non-small-cell lung cancer (NSCLC) is extremely aggressive, owing to an accumulation of mutations that affect the cancer pathways RAS and p53.” The K-RAS mutation is found in about 25 percent of NSCLC patients, and the p53 mutation is found in about 50 percent of these patients. Researchers said “Our research group and others have found that both of these microRNAs can inhibit tumor growth in a variety of cells and animal model systems when used as therapeutic agents.” Because tumor formation in the NSCLC model depends on two or more signaling pathways, and because let-7 and miR-34 repress distinct oncogenes, we explored whether combining let-7 and miR-34 into a single therapeutic could be even more effective.” .Half the dose of each was used in cells and in vivo and were well tolerated by animals.